Abstract:Abstract Background Cancer metastasis is a complex process involving the spread of malignant cells from a primary tumor to distal organs. Understanding this cascade at a mechanistic level could provide critical new insights into the disease and potentially reveal new avenues for treatment. Transcriptome profiling of spontaneous cancer models is an attractive method to examine the dynamic changes accompanying tumor cell spread. However, such studies are complicated by the underlying heterogeneity of the cell types involved. The purpose of this study was to examine the transcriptomes of metastatic breast cancer cells using the well-established MMTV-PyMT mouse model. Methods Organ-derived metastatic cell lines were harvested from 10 female MMTV-PyMT mice. Cancer cells were isolated and sorted based on the expression of CD44 low /EpCAM high or CD44 high /EpCAM high surface markers. RNA from each cell line was extracted and sequenced using the NextSeq 500 Illumina platform. Tissue-specific genes were compared across the different metastatic and primary tumor samples. Reads were mapped to the mouse genome using STAR, and gene expression was quantified using RSEM. Single-cell RNA-seq (scRNA-seq) was performed on select samples using the ddSeq platform by BioRad and analyzed using Seurat v3.2.3. Monocle2 was used to infer pseudo-time progression. Results Comparison of RNA sequencing data across all cell populations produced distinct gene clusters. Differential gene expression patterns related to CD44 expression, organ tropism, and immunomodulatory signatures were observed. scRNA-seq identified expression profiles based on tissue-dependent niches and clonal heterogeneity. These cohorts of data were narrowed down to identify subsets of genes with high expression and known metastatic propensity. Dot plot analyses further revealed clusters expressing cancer stem cell and cancer dormancy markers. Changes in relevant genes were investigated across pseudo-time and tissue origin using Monocle2. These data revealed transcriptomes that may contribute to sub-clonal evolution and treatment evasion during cancer progression. Conclusions We performed a comprehensive transcriptome analysis of tumor heterogeneity and organ tropism during breast cancer metastasis. These data add to our understanding of metastatic progression and highlight targets for breast cancer treatment. These markers could also be used to image the impact of tumor heterogeneity on metastases.

Organ-Specificity of Breast Cancer Metastasis

Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment

Organotropism: new insights into molecular mechanisms of breast cancer metastasis

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

Mechanisms Involved in Breast Cancer Liver Metastasis

THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF BREAST CANCER BRAIN METASTASIS

Transcriptomic analysis identifies organ-specific metastasis genes and pathways across different primary sites

Recent advances in breast cancer metastasis with special emphasis on metastasis to the brain

Cell-cell communication characteristics in breast cancer metastasis

Concise review: breast cancer stems cells and their role in metastases

Organ-specific immune setpoints underlie divergent immune profiles across metastatic sites in breast cancer

Gene expression profiles of breast cancer metastasis according to organ site

Mapping the niche of breast cancer metastases in lung and liver

Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools

Breast cancer intratumour heterogeneity: current status and clinical implications

Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

[When a metastasis hides another]

Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity

Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer